Immune and epithelial determinants of age-related risk and alveolar injury in fatal COVID-19
Authors:
- Michael ChaitMCMichael Chait
- Mine M. YilmazMYMine M. Yilmaz
- Shanila ShakilSSShanila Shakil
- Amy W. KuAKAmy W. Ku
- Pranay DograPDPranay Dogra
- Thomas J. ConnorsTCThomas J. Connors
- Peter A. SzaboPSPeter A. Szabo
- Joshua I. GrayJGJoshua I. Gray
- Steven B. WellsSWSteven B. Wells
- Masaru KubotaMKMasaru Kubota
- Rei MatsumotoRMRei Matsumoto
- Maya M.L. PoonMPMaya M.L. Poon
Open Access
- 8 June 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (11) , 1-19
Abstract
Respiratory failure in COVID-19 is characterized by widespread disruption of the lung’s alveolar gas exchange interface. To elucidate determinants of alveolar lung damage, we performed epithelial and immune cell profiling in lungs from 24 COVID-19 autopsies and 43 uninfected organ donors ages 18–92 years. We found marked loss of type 2 alveolar epithelial (T2AE) cells and increased perialveolar lymphocyte cytotoxicity in all fatal COVID-19 cases, even at early stages before typical patterns of acute lung injury are histologically apparent. In lungs from uninfected organ donors, there was also progressive loss of T2AE cells with increasing age, which may increase susceptibility to COVID-19–mediated lung damage in older individuals. In the fatal COVID-19 cases, macrophage infiltration differed according to the histopathological pattern of lung injury. In cases with acute lung injury, we found accumulation of CD4 + macrophages that expressed distinctly high levels of T cell activation and costimulation genes and strongly correlated with increased extent of alveolar epithelial cell depletion and CD8 + T cell cytotoxicity. Together, our results show that T2AE cell deficiency may underlie age-related COVID-19 risk and initiate alveolar dysfunction shortly after infection, and we define immune cell mediators that may contribute to alveolar injury in distinct pathological stages of fatal COVID-19.Keywords
Funding Information
- NIH Office of the Director (P30CA013696)
- Chan Zuckerberg Initiative (Single-Cell COVID-19 Consortium)
- CRI-Irvington (Postdoctoral Fellowship)
- Canadian Institutes of Health Research (Research fellowship)
- NIH Office of the Director (HL145547,AI128949,AI106697,DK122130,AI141686)
This publication has 66 references indexed in Scilit:
- Overexpression of CD163, CD204 and CD206 on Alveolar Macrophages in the Lungs of Patients with Severe Chronic Obstructive Pulmonary DiseasePLOS ONE, 2014
- Type 2 alveolar cells are stem cells in adult lungJournal of Clinical Investigation, 2013
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- Amphiregulin, an Epidermal Growth Factor Receptor Ligand, Plays an Essential Role in the Pathogenesis of Transforming Growth Factor-β-induced Pulmonary FibrosisJournal of Biological Chemistry, 2012
- HTII-280, a Biomarker Specific to the Apical Plasma Membrane of Human Lung Alveolar Type II CellsJournal of Histochemistry & Cytochemistry, 2010
- Pulmonary Surfactant Surface Tension Influences Alveolar Capillary Shape and OxygenationAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lungClinical Science, 2008
- Resident Alveolar Macrophages Are Replaced by Recruited Monocytes in Response to Endotoxin-Induced Lung InflammationAmerican Journal of Respiratory Cell and Molecular Biology, 2006
- Involvement of Napsin A in the C- and N-terminal Processing of Surfactant Protein B in Type-II Pneumocytes of the Human LungJournal of Biological Chemistry, 2003
- Human Tissue Distribution of TA02, Which is Homologous with a New Type of Aspartic Proteinase, Napsin AJapanese Journal of Cancer Research, 2000